Management of OAB in Female Patients .

Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial

The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

Inclusion Criteria:

• Women from 18 to 65 years of age with LUTs due to OAB

Exclusion Criteria:

• Severe cardiovascular disorders. \

  • Severe neurogenic dysfunction.
  • Drug administration which interfere with bladder function .
  • Abnormal bleeding profile.
  • A verified urinary tract infection as determined by urinalysis and/or urine culture during screening